Medical Oncology Specialist Prof. Dr. Serdar Turhal said, “This study was based on a study conducted in the past years, which showed that the genetic risk calculation was performed in breast cancer patients who did not spread to the underarm lymph, and that chemotherapy could be as good as chemotherapy, without chemotherapy alone.
In this new study, Oncology Specialist Prof. Dr. Serdar Turhal said, “2/3 of the patients were in menopause and 1/3 were patients who had not yet entered menopause. In this study, only hormone therapy was given to some of the patients whose genetic recurrence risk was calculated to be low, and some of them both chemotherapy and hormone therapy ”.
Prof. Dr. Serdar Turhal continued his explanations as follows: “While there is an additional contribution of 1.3 percent of chemotherapy in women who have not entered menopause and have a low genetic recurrence score in the five-year follow-up, such an additional benefit of chemotherapy was not shown in women who entered menopause. As a result, it has been shown that only anti-hormone therapy can be as effective as chemotherapy in patients with positive hormone receptors and entering menopause. “